Of the patients, 25% (3/12) had mutations in cancer driver genes such as TP53, ATM, and SETD2, while 16.7% (2/12) had mutations in cancer driver genes such as ATRX, EP300, FGFR2, KRAS, NOCR1, and RB1. The gene discussed is KRAS; the disease is cancer.